| Prev Close: | 43.54 |
|---|
| Open: | N/A |
|---|
| Bid: | 41.75 x 100 |
|---|
| Ask: | 99.00 x 100 |
|---|
| 1y Target Est: | 47.05 |
|---|
| Beta: | 1.810 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 33.33 - 48.00 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 6,191,740 |
|---|
| Market Cap: | 68.96B |
|---|
| P/E (ttm): | 12.88 |
|---|
| EPS (ttm): | 3.38 |
|---|
| Div & Yield: | 1.60 (3.70%) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Supreme Court satisfies few with ruling on generic drug settlementsat MarketWatch(Tue, Jun 18)
- "Pay-For Delay" Was Fun While It Lastedat Motley Fool(Tue, Jun 18)
- Dan Loeb's cheap stock picksat MarketWatch(Tue, Jun 18)
- Pharma payments to delay generic rivals to be scrutinisedat Financial Times(Mon, Jun 17)
- Drugmakers Opened to ‘Pay for Delay’ Suits by High Courtat Bloomberg(Mon, Jun 17)
- Court: 'Pay to delay' generic drugs can be illegalAP(Mon, Jun 17)
- Abbott Loves Abbott Laboratories Stockat Motley Fool(Mon, Jun 17)
- Successor To Humira? AbbVie And Galapagos Work On Itat Seeking Alpha(Mon, Jun 17)
- American Generics Can't Touch This $8 Billion Drug (Yet)at Motley Fool(Mon, Jun 17)
- Supreme Court decision on generics hits Actavis, but few other drug firmsat MarketWatch(Mon, Jun 17)
- Supreme Court Tells FTC And Drug Industry To Go To Warat Forbes(Mon, Jun 17)
- Data on BMY/ AbbVie's elotuzumabZacks(Mon, Jun 17)
- U.S. justices say FTC can challenge deals to keep generic drugs off marketat Reuters(Mon, Jun 17)
- Gilead's Potential Megablockbuster Raises the Barat Motley Fool(Mon, Jun 17)
- AbbVie announces preliminary results in Phase 1 study of ABT-199theflyonthewall.com(Mon, Jun 17)
Key Statistics
| Forward P/E (1 yr): | 13.48 |
|---|
| P/S (ttm): | 3.72 |
|---|
| Ex-Dividend Date: | 11-Apr-13 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | 3.12 |
|---|
| Quarterly EPS Est
(Jun-13)
: | 0.79 |
|---|
| Mean Recommendation*: | 2.3 |
|---|
| PEG Ratio (5 yr expected): | 2.05 |
|---|
Business Summary
AbbVie Inc., a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide.
View More